Tuba T. Duman

Bolu, 14280, Turkey

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Hepatic fibrosis severity assessed by FIB-4 index is independently associated with reduced kidney function in patients with metabolic dysfunction-associated steatotic liver disease: a nationwide multicenter study from Türkiye.

Hepatic fibrosis severity assessed by FIB-4 index is independently associated with reduced kidney function in patients with metabolic dysfunction-associated steatotic liver disease: a nationwide multicenter study from Türkiye.

Journal: Hepatology international

Published: April 25, 2026

Associations of Mediterranean, DASH, and MIND diet adherence with metabolic parameters in individuals with type 2 diabetes mellitus: a cross-sectional study.

Associations of Mediterranean, DASH, and MIND diet adherence with metabolic parameters in individuals with type 2 diabetes mellitus: a cross-sectional study.

Journal: Irish journal of medical science

Published: February 03, 2026

The role of lipid-derived indices in patients with MASLD in Turkey: a nationwide, multicenter cross-sectional study.

The role of lipid-derived indices in patients with MASLD in Turkey: a nationwide, multicenter cross-sectional study.

Journal: Scientific reports

Published: December 09, 2025

Controlling Nutritional Status (CONUT) score is a novel marker of type 2 diabetes mellitus and diabetic microvascular complications.

Controlling Nutritional Status (CONUT) score is a novel marker of type 2 diabetes mellitus and diabetic microvascular complications.

Journal: Postgraduate medicine

Published: June 26, 2024

Effect of sodium glucose Co-transporter 2 inhibitor use on anthropometric measurements and blood glucose in obese and non-obese type 2 diabetic patients.

Effect of sodium glucose Co-transporter 2 inhibitor use on anthropometric measurements and blood glucose in obese and non-obese type 2 diabetic patients.

Journal: Clinical nutrition ESPEN

Published: May 25, 2024

A novel marker for prediabetic conditions: Uric acid-to-HDL cholesterol ratio.

A novel marker for prediabetic conditions: Uric acid-to-HDL cholesterol ratio.

Journal: Bratislavske lekarske listy

Published: February 22, 2024

Is serum uric acid-to-HDL cholesterol ratio elevation associated with diabetic kidney injury?

Is serum uric acid-to-HDL cholesterol ratio elevation associated with diabetic kidney injury?

Journal: Postgraduate medicine

Published: May 12, 2023

A Novel Inflammatory Marker for the Diagnosis of Hashimoto's Thyroiditis: Platelet-Count-to-Lymphocyte-Count Ratio.

A Novel Inflammatory Marker for the Diagnosis of Hashimoto's Thyroiditis: Platelet-Count-to-Lymphocyte-Count Ratio.

Journal: Diseases (Basel, Switzerland)

Published: December 15, 2022

C-reactive protein-to-lymphocyte ratio is a reliable marker in patients with COVID-19 infection: the CLEAR COVID study.

C-reactive protein-to-lymphocyte ratio is a reliable marker in patients with COVID-19 infection: the CLEAR COVID study.

Journal: Cirugia y cirujanos

Published: November 03, 2022

C-reactive protein to lymphocyte count ratio is a promising novel marker in hepatitis C infection: the clear hep-c study.

C-reactive protein to lymphocyte count ratio is a promising novel marker in hepatitis C infection: the clear hep-c study.

Journal: Revista da Associacao Medica Brasileira (1992)

Published: March 10, 2022

Poorly controlled hypertension is associated with elevated serum uric acid to HDL-cholesterol ratio: a cross-sectional cohort study.

Poorly controlled hypertension is associated with elevated serum uric acid to HDL-cholesterol ratio: a cross-sectional cohort study.

Journal: Postgraduate medicine

Published: February 10, 2022

Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study.

Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study.

Journal: Irish journal of medical science

Published: August 14, 2021

Showing 1-12 of 37

Last Updated: 09/26/2026